GlaxoSmithKline's COPD drug Anoro receives European green light

February 20, 2014 1:35 PM

8 0

GlaxoSmithKline's COPD drug Anoro receives European green light

LONDON (Reuters) - Anoro, a combination drug for chronic obstructive pulmonary disease (COPD) developed by GlaxoSmithKline and Theravance, has received the green light from European regulators, the companies said on Thursday.

The drug is a combination of UMEC, a long-acting muscarinic antagonist, and VI, a long-acting beta agonist, in a single inhaler. It is expected to generate sales of more than $2 billion a year by 2018, according to the average estimate of six analysts polled by Thomson Reuters.

Read more

To category page

Loading...